Founded in 2007 and headquartered in Gaithersburg, MD, Amplimmune is focused on developing novel biologics that rebalance the immune system. These novel immunoregulatory drugs are being developed for the treatment of cancer, autoimmune disease, infectious disease, and transplantation. With its strong product-based focus, Amplimmune is rapidly advancing two lead molecules toward clinical development: AMP-224 in the area of cancer and infectious disease; and AMP-110 for autoimmune diseases. Working closely with its collaborators, Amplimmune is expanding its technology base in the area of immune regulatory molecules and has assembled a large foundation of reagents, models, know-how, and intellectual property to further develop its product pipeline as well as to discover novel biomarkers, ligands, and receptors. In August of 2010, Amplimmune and GlaxoSmithKline entered into a partnership and global strategic collaboration on the AMP-224 program. The company is funded by InterWest Partners and The Wellcome Trust.